Nls Pharmaceutics Ag Stock Working Capital

NLSPW Stock  USD 0.01  0.0005  3.57%   
NLS Pharmaceutics AG fundamentals help investors to digest information that contributes to NLS Pharmaceutics' financial success or failures. It also enables traders to predict the movement of NLS Stock. The fundamental analysis module provides a way to measure NLS Pharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NLS Pharmaceutics stock.
Last ReportedProjected for Next Year
Net Working Capital-7 M-6.7 M
Change In Working Capital2.6 M2.7 M
Change In Working Capital is likely to climb to about 2.7 M in 2025, despite the fact that Net Working Capital is likely to grow to (6.7 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NLS Pharmaceutics AG Company Working Capital Analysis

NLS Pharmaceutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current NLS Pharmaceutics Working Capital

    
  (6.1 M)  
Most of NLS Pharmaceutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NLS Pharmaceutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

NLS Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for NLS Pharmaceutics is extremely important. It helps to project a fair market value of NLS Stock properly, considering its historical fundamentals such as Working Capital. Since NLS Pharmaceutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NLS Pharmaceutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NLS Pharmaceutics' interrelated accounts and indicators.
0.85-0.76-0.40.01-0.30.27-0.630.420.990.560.410.140.420.410.390.46
0.85-0.72-0.16-0.11-0.260.27-0.680.490.850.680.060.420.250.060.550.28
-0.76-0.720.75-0.550.83-0.820.780.19-0.72-0.02-0.63-0.55-0.77-0.63-0.47-0.8
-0.4-0.160.75-0.840.84-0.830.410.59-0.380.46-0.96-0.13-0.85-0.96-0.14-0.88
0.01-0.11-0.55-0.84-0.850.89-0.13-0.84-0.04-0.750.730.350.860.73-0.010.84
-0.3-0.260.830.84-0.85-0.980.60.7-0.240.52-0.71-0.61-0.84-0.71-0.29-0.85
0.270.27-0.82-0.830.89-0.98-0.53-0.680.22-0.510.690.60.870.680.290.87
-0.63-0.680.780.41-0.130.6-0.53-0.01-0.61-0.18-0.37-0.5-0.33-0.37-0.58-0.38
0.420.490.190.59-0.840.7-0.68-0.010.470.97-0.51-0.31-0.54-0.510.13-0.53
0.990.85-0.72-0.38-0.04-0.240.22-0.610.470.610.40.060.360.40.380.41
0.560.68-0.020.46-0.750.52-0.51-0.180.970.61-0.43-0.14-0.41-0.430.27-0.4
0.410.06-0.63-0.960.73-0.710.69-0.37-0.510.4-0.43-0.060.751.00.030.78
0.140.42-0.55-0.130.35-0.610.6-0.5-0.310.06-0.14-0.060.31-0.070.220.3
0.420.25-0.77-0.850.86-0.840.87-0.33-0.540.36-0.410.750.310.740.321.0
0.410.06-0.63-0.960.73-0.710.68-0.37-0.510.4-0.431.0-0.070.740.030.78
0.390.55-0.47-0.14-0.01-0.290.29-0.580.130.380.270.030.220.320.030.34
0.460.28-0.8-0.880.84-0.850.87-0.38-0.530.41-0.40.780.31.00.780.34
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

NLS Capital Surpluse

Capital Surpluse

17.11 Million

At this time, NLS Pharmaceutics' Capital Surpluse is fairly stable compared to the past year.
Based on the company's disclosures, NLS Pharmaceutics AG has a Working Capital of (6.1 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is notably higher than that of the company.

NLS Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NLS Pharmaceutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NLS Pharmaceutics could also be used in its relative valuation, which is a method of valuing NLS Pharmaceutics by comparing valuation metrics of similar companies.
NLS Pharmaceutics is currently under evaluation in working capital category among its peers.

NLS Pharmaceutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of NLS Pharmaceutics from analyzing NLS Pharmaceutics' financial statements. These drivers represent accounts that assess NLS Pharmaceutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NLS Pharmaceutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap557.1M654.8M1.0B897.9M1.0B1.1B
Enterprise Value559.1M649.4M1.0B898.6M1.0B1.1B

NLS Fundamentals

About NLS Pharmaceutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.